Special Report

Convection-enhanced delivery for glioblastoma: targeted delivery of antitumor therapeutics

Timothy H Ung

*Author for correspondence:

E-mail Address: TU2142@columbia.edu

Department of Neurological Surgery, Columbia University Medical Center, New York, NY 10032, USA

Search for more papers by this author

Hani Malone

Department of Neurological Surgery, Columbia University Medical Center, New York, NY 10032, USA

Search for more papers by this author

Peter Canoll

Department of Pathology & Cellular Biology, Columbia University Medical Center, New York, NY 10032, USA

Search for more papers by this author

Jeffrey N Bruce

Department of Neurological Surgery, Columbia University Medical Center, New York, NY 10032, USA

Search for more papers by this author

Published Online:24 Jun 2015https://doi.org/10.2217/cns.15.12

View article

Abstract

SUMMARY

Glioblastoma is the most common primary brain tumor in adults and carries a dismal prognosis despite advancements in treatment. Diffuse tumor infiltration precludes curative surgical resection and necessitates advancements in drug delivery mechanisms. Convection-enhanced delivery (CED) enables continuous local drug delivery for a diverse population of antitumor agents. Importantly, CED circumvents therapeutic challenges posed by the blood–brain barrier by facilitating concentrated local therapeutic drug delivery with limited systemic effects. Here, we present a concise review of properties essential for safe and efficient convection-enhanced drug delivery, as well as a focused review of clinical studies evaluating CED in the treatment of glioblastoma.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2(9), 494–503; quiz 491 p following 516 (2006).Crossref, Medline, Google Scholar
2 Garrido W, Rocha JD, Jaramillo C et al. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme. Curr. Drug Targets 15(10), 931–942 (2014).Crossref, Medline, CAS, Google Scholar
3 Ho VK, Reijneveld JC, Enting RH et al. Changing incidence and improved survival of gliomas. Eur. J. Cancer 50(13), 2309–2318 (2014).Crossref, Medline, Google Scholar
4 Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).•• Illustrates current standard of care for glioblastoma.Crossref, Medline, CAS, Google Scholar
5 Lee SW, Fraass BA, Marsh LH et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int. J. Radiat. Oncol. Biol. Phys. 43(1), 79–88 (1999).Crossref, Medline, CAS, Google Scholar
6 Halperin EC, Burger PC, Bullard DE. The fallacy of the localized supratentorial malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 15(2), 505–509 (1988).Crossref, Medline, CAS, Google Scholar
7 Vogel TW, Bruce, Jeffrey N. Local delivery methods into the CNS. Minim. Invasive Neurosurg. 297–316 (2005).Crossref, Medline, Google Scholar
8 Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA 91(6), 2076–2080 (1994).•• Illustrates initial efforts in convection-enhanced delivery of macromolecules into the brain. Significant work in safe delivery of molecules to the brain.Crossref, Medline, CAS, Google Scholar
9 Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med. 3(12), 1362–1368 (1997).Crossref, Medline, CAS, Google Scholar
10 Lopez KA, Waziri AE, Canoll PD, Bruce JN. Convection-enhanced delivery in the treatment of malignant glioma. Neurol. Res. 28(5), 542–548 (2006).Crossref, Medline, Google Scholar
11 Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J. Neurosurg. 90(2), 315–320 (1999).Crossref, Medline, CAS, Google Scholar
12 Barua NU, Gill SS, Love S. Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. Brain Pathol. 24(2), 117–127 (2014).Crossref, Medline, CAS, Google Scholar
13 Barua NU, Lowis SP, Woolley M, O'Sullivan S, Harrison R, Gill SS. Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma. Acta Neurochir. (Wien) 155(8), 1459–1465 (2013).Crossref, Medline, CAS, Google Scholar
14 Lonser RR, Walbridge S, Garmestani K et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J. Neurosurg. 97(4), 905–913 (2002).Crossref, Medline, Google Scholar
15 Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J. Neurooncol. 73(1), 57–69 (2005).Crossref, Medline, Google Scholar
16 Hadaczek P, Yamashita Y, Mirek H et al. The “perivascular pump” driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol. Ther. 14(1), 69–78 (2006).• Cardiac and vascular flow considerations in distribution volume of convection-enhanced delivery therapeutics for antiglioma agents.Crossref, Medline, CAS, Google Scholar
17 Groothuis DR, Ward S, Itskovich AC et al. Comparison of ¹⁴C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J. Neurosurg. 90(2), 321–331 (1999).• Demonstrates intracerebral infusion with isotope labeling.Crossref, Medline, CAS, Google Scholar
18 Groothuis DR. The blood–brain and blood–tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2(1), 45–59 (2000).Crossref, Medline, CAS, Google Scholar
19 Sampson JH, Raghavan R, Brady ML et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol. 9(3), 343–353 (2007).Crossref, Medline, CAS, Google Scholar
20 Olson JJ, Zhang Z, Dillehay D, Stubbs J. Assessment of a balloon-tipped catheter modified for intracerebral convection-enhanced delivery. J. Neurooncol. 89(2), 159–168 (2008).Crossref, Medline, Google Scholar
21 Bruce JN, Fine RL, Canoll P et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69(6), 1272–1279; discussion 1279–1280 (2011).Crossref, Medline, Google Scholar
22 Lopez KA, Tannenbaum AM, Assanah MC et al. Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res. 71(11), 3963–3971 (2011).Crossref, Medline, CAS, Google Scholar
23 Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47(6), 1391–1398; discussion 1398–1399 (2000).Crossref, Medline, CAS, Google Scholar
24 Sonabend AM, Stuart RM, Yun J et al. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol. 13(8), 886–893 (2011).• Prolonged treatment with subcutaneous implanted catheter.Crossref, Medline, CAS, Google Scholar
25 Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6(10), 789–802 (2006).Crossref, Medline, CAS, Google Scholar
26 Burch PA, Bernath AM, Cascino TL et al. A North Central Cancer Treatment Group Phase II trial of topotecan in relapsed gliomas. Invest. New Drugs 18(3), 275–280 (2000).Crossref, Medline, CAS, Google Scholar
27 Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J. Neurosci. 26(25), 6781–6790 (2006).Crossref, Medline, CAS, Google Scholar
28 Yun J, Rothrock RJ, Canoll P, Bruce JN. Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. J. Drug Deliv. 2013, 107573 (2013).Crossref, Medline, Google Scholar
29 Huncharek M, Kupelnick B, Bishop D. Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat. Rev. 24(5), 307–316 (1998).Crossref, Medline, CAS, Google Scholar
30 Dodion P, Sanders C, Georges P, Kenis Y. In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother. Pharmacol. 22(1), 80–82 (1988).Crossref, Medline, CAS, Google Scholar
31 Cohen JD, Robins HI, Javid MJ. Sensitization of C6 glioma to carboplatin cytotoxicity by hyperthermia and thymidine. J. Neurooncol. 9(1), 1–8 (1990).Crossref, Medline, CAS, Google Scholar
32 Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J. Cancer Res. Clin. Oncol. 125(8–9), 481–486 (1999).Crossref, Medline, CAS, Google Scholar
33 Murray LJ, Bridgewater CH, Levy D. Carboplatin chemotherapy in patients with recurrent high-grade glioma. Clin. Oncol. (R. Coll. Radiol.) 23(1), 55–61 (2011).Crossref, Medline, CAS, Google Scholar
34 Warnick RE, Prados MD, Mack EE et al. A Phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J. Neurooncol. 19(1), 69–74 (1994).Crossref, Medline, CAS, Google Scholar
35 Cloughesy TF, Gobin YP, Black KL et al. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J. Neurooncol. 35(2), 121–131 (1997).Crossref, Medline, CAS, Google Scholar
36 Stewart DJ, Belanger JM, Grahovac Z et al. Phase I study of intracarotid administration of carboplatin. Neurosurgery 30(4), 512–516; discussion 516–517 (1992).Crossref, Medline, CAS, Google Scholar
37 Fortin D, Gendron C, Boudrias M, Garant MP. Enhanced chemotherapy delivery by intraarterial infusion and blood–brain barrier disruption in the treatment of cerebral metastasis. Cancer 109(4), 751–760 (2007).Crossref, Medline, CAS, Google Scholar
38 Barua NU, Hopkins K, Woolley M et al. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma. Drug Deliv. doi:10.3109/10717544.2014.908248 (2014) (Epub ahead of print).Medline, Google Scholar
39 White E, Bienemann A, Taylor H, Hopkins K, Cameron A, Gill S. A Phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. Contemp. Clin. Trials 33(2), 320–331 (2012).Crossref, Medline, CAS, Google Scholar
40 Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 60(5), 1168–1172 (2000).•• Illustrates increased expression of IL-13 in human malignant glioma.Medline, CAS, Google Scholar
41 Shimamura T, Husain SR, Puri RK. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg. Focus 20(4), E11 (2006).Crossref, Medline, Google Scholar
42 Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92(2), 168–175 (2001).Crossref, Medline, CAS, Google Scholar
43 Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 65(1), 37–48 (2003).Crossref, Medline, Google Scholar
44 Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25(7), 837–844 (2007).Crossref, Medline, CAS, Google Scholar
45 Jiang H, Clise-Dwyer K, Ruisaard KE et al. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS ONE 9(5), e97407 (2014).Crossref, Medline, Google Scholar
46 Fueyo J, Alemany R, Gomez-Manzano C et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl Cancer Inst. 95(9), 652–660 (2003).Crossref, Medline, CAS, Google Scholar
47 Goetz C, Gromeier M. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev. 21(2–3), 197–203 (2010).Crossref, Medline, CAS, Google Scholar
48 Desjardins A, Sampson JH, Peters KB et al. Oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM): first Phase I clinical trial evaluating the intratumoral administration. Neuro Oncol. 16(Suppl. 3), iii43–iii43 (2014).Crossref, Google Scholar
49 ClinicalTrials.gov. https://clinicaltrials.gov/.Google Scholar

Vol. 4, No. 4

Metrics

Downloaded 129 times

History

Published online 24 June 2015

Published in print July 2015

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download